Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference
Oncocyte Corporation (Nasdaq: OCX) will present at the Lake Street 6th Annual Best Ideas Growth Conference on September 14, 2022, at the Yale Club in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oncocyte Corporation (Nasdaq: OCX) will present at the Lake Street 6th Annual Best Ideas Growth Conference on September 14, 2022, at the Yale Club in New York City. The company focuses on precision diagnostics to improve patient outcomes through personalized insights. Its proprietary tests, including DetermaRx™ for lung cancer recurrence risk and DetermaIO™ for immunotherapy response prediction, aim to enhance cancer care. Oncocyte also offers pharmaceutical services for molecular testing to support new cancer treatment development.
Details
News Market Reaction – OCX
The recorded move for OCX in the trading session of this news was -0.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that its management team will participate at the Lake Street 6th Annual Best Ideas Growth Conference on Wednesday, September 14, 2022 at the Yale Club in New York City, NY.
About Oncocyte
Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.
Through its proprietary tests and pharmaceutical services business, the Company aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients at every stage. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The Company’s pipeline of tests in development also includes DetermaTx™, which will assess mutational status of a tumor, DetermaCNI™, a blood-based monitoring test, DetermaMx™, a long-term recurrence monitoring test, and VitaGraft™, a blood-based solid organ transplantation monitoring test. In addition, Oncocyte’s pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.
DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and VitaGraft™ are trademarks of Oncocyte Corporation.
Investor & Media Contact
Caroline Corner
ICR Westwicke
Tel: 415.202.5678
caroline.corner@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.